ArticleCell death & disease2025
Low SVEP1 in intrahepatic cholangiocarcinoma mediates phenotype switching-driven metastasis by Jag2/Notch1/Hes5.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a distinct and increasingly prevalent subtype of cholangiocarcinoma arising from the epithelial cells of the intrahepatic bile ducts. Its molecular diversity contributes to its highly aggressive nature and resistance to chemotherapy. SVEP1 (sushi, Von Willebrand factor type A, EGF, and pentaxin) is a multi-domain extracellular matrix (ECM) protein that is vital for embryogenesis, cell-cell adhesion, and the maintenance of epidermal differentiation. However, the specific effect of SVEP1 on the occurrence and progression of ICC remains poorly understood. Therefore, this study aims to examine the role of SVEP1 in ICC. We first identified SVEP1 using high-throughput RNA sequencing in two groups of patients with ICC with different disease-free survival rates. We further analyzed the expression pattern of SVEP1 in ICC using various public datasets and clinical tissue samples, exploring the correlation between SVEP1 depletion and ICC clinical prognosis. The regulatory role of SVEP1 depletion in ICC progression was studied using in vitro and in vivo experiments. We found that decreased SVEP1 expression positively correlates with early recurrence and shorter overall survival in ICC. Moreover, SVEP1 downregulation was correlated with multiple poor prognostic parameters, including positive lymph nodes, satellite nodes, and high Ki-67 expression. Downregulated SVEP1 expression promoted ICC cell proliferation, chemotactic migration, and invasion in vitro, as well as tumor growth and lung metastasis in vivo. These effects were mediated by EMT phenotype switching through the activation of the Jag2/Notch1/Hes5 pathway. Our findings enhance the understanding of the novel mechanisms driving ICC progression and metastasis, suggesting that SVEP1 is a potential biomarker for ICC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.